Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials

Background Evidence on preventing Alzheimer’s disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention. Methods Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised. Results A total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B). Interpretation Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.

[1]  Hannah Stower.  Linking Alzheimer’s disease and frailty , 2019, Nature Medicine.

[2]  B. Sheehan,et al.  Dementia And Physical Activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial , 2018, British Medical Journal.

[3]  J. Weuve,et al.  Blood pressure and risk of incident Alzheimer's disease dementia by antihypertensive medications and APOE ε4 allele , 2018, Annals of neurology.

[4]  M. Jokela,et al.  Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals , 2018, Alzheimer's & Dementia.

[5]  L. Hemmy,et al.  Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia , 2018, Annals of Internal Medicine.

[6]  Quincy M. Samus,et al.  Dementia prevention, intervention, and care , 2017, The Lancet.

[7]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[8]  G. Joyce,et al.  Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease , 2017, JAMA neurology.

[9]  L. Hemmy,et al.  Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia , 2017 .

[10]  L. Schneider,et al.  Defeating Alzheimer's disease and other dementias: a priority for European science and society , 2016, The Lancet Neurology.

[11]  C. Mazure,et al.  Sex differences in Alzheimer's disease and other dementias , 2016, The Lancet Neurology.

[12]  C. Dufouil,et al.  Incidence of Dementia over Three Decades in the Framingham Heart Study. , 2016, The New England journal of medicine.

[13]  Antonio Lobo,et al.  Dementia in western Europe: epidemiological evidence and implications for policy making , 2016, The Lancet Neurology.

[14]  Bruno Vellas,et al.  Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions , 2015, The Lancet Neurology.

[15]  Lars Bäckman,et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.

[16]  R. Kryscio.  Secondary prevention trials in Alzheimer disease: the challenge of identifying a meaningful end point. , 2014, JAMA neurology.

[17]  J. Bond,et al.  A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II , 2013, The Lancet.

[18]  B. Winblad,et al.  Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden , 2013, Neurology.

[19]  G. Rosenberg.  Reversion from mild cognitive impairment to normal or near-normal cognition: Risk factors and prognosis , 2013, Neurology.

[20]  Thomas D Koepsell,et al.  Reversion from mild cognitive impairment to normal or near-normal cognition , 2012, Neurology.

[21]  Gordon H Guyatt,et al.  GRADE guidelines: 7. Rating the quality of evidence--inconsistency. , 2011, Journal of clinical epidemiology.

[22]  G. Guyatt,et al.  GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.

[23]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[24]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[25]  Richard D Riley,et al.  Interpretation of random effects meta-analyses , 2011, BMJ : British Medical Journal.

[26]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[27]  B. Vellas,et al.  Dementia prevention: methodological explanations for inconsistent results. , 2008, Epidemiologic reviews.

[28]  Alex J Sutton,et al.  Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. , 2008, Journal of clinical epidemiology.

[29]  A. Zonderman,et al.  Depressive symptoms, sex, and risk for Alzheimer's disease , 2005, Annals of neurology.

[30]  S. Resnick,et al.  Free testosterone and risk for Alzheimer disease in older men , 2004, Neurology.

[31]  F. Song,et al.  Evaluating non-randomised intervention studies. , 2003, Health technology assessment.

[32]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[33]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[34]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[35]  B. Winblad,et al.  Influence of social network on occurrence of dementia: a community-based longitudinal study , 2000, The Lancet.

[36]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[37]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.